HAVN Life Sciences(TSE:HAVN)
CA$0.030.00 (0.00%)
TSE:HAVN
HAVN Life Sciences financials statements
CA$0.03
At close:0.00 (0.00%)
HAVN Life Sciences (HAVN) Ratios
13 Followers
HAVN Life Sciences Ratios
TSE:HAVN's free cash flow for Q3 2023 was C$289.12K. For the 2023 fiscal year, TSE:HAVN's free cash flow was decreased by C$-1.00 and operating cash flow was C$289.12K. See a summary of the company’s cash flow.
| Ratios | Jul 21 | Apr 20 |
|---|---|---|
| Liquidity Ratios | ||
| Current Ratio | 14.84 | 47.25 |
| Quick Ratio | 14.34 | 53.35 |
| Cash Ratio | 13.15 | 39.33 |
| Solvency Ratio | -24.80 | 3.19 |
| Operating Cash Flow Ratio | -14.58 | -1.82 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 |
| Net Current Asset Value | C$ 9.57M | C$ 1.90M |
| Leverage Ratios | ||
| Debt-to-Assets Ratio | 0.03 | 0.00 |
| Debt-to-Equity Ratio | 0.03 | 0.00 |
| Debt-to-Capital Ratio | 0.03 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.08 | 1.02 |
| Debt Service Coverage Ratio | -1472.34 | 0.00 |
| Interest Coverage Ratio | -1734.96 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 |
| Interest Debt Per Share | 0.13 | 0.00 |
| Net Debt to EBITDA | 0.35 | 39.85 |
| Profitability Margins | ||
| Gross Profit Margin | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% |
| EBT Per EBIT | 100.09% | 100.00% |
| Return on Assets (ROA) | -213.34% | -2.09% |
| Return on Equity (ROE) | -230.16% | -2.13% |
| Return on Capital Employed (ROCE) | -224.42% | -2.13% |
| Return on Invested Capital (ROIC) | -222.27% | 23.47% |
| Return on Tangible Assets | -268.63% | -2.09% |
| Earnings Yield | -39.75% | -2.13% |
| Efficiency Ratios | ||
| Receivables Turnover | 0.00 | 0.00 |
| Payables Turnover | 8.61 | 0.00 |
| Inventory Turnover | 12.82 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 |
| Cash Conversion Cycle | -13.91 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 |
| Days of Inventory Outstanding | 28.48 | 0.00 |
| Days of Payables Outstanding | 42.39 | 0.00 |
| Operating Cycle | 28.48 | 0.00 |
| Cash Flow Ratios | ||
| Operating Cash Flow Per Share | -2.90 | -0.72 |
| Free Cash Flow Per Share | -2.91 | -0.72 |
| Dividend Paid and CapEx Coverage Ratio | -319.57 | 0.00 |
| Capital Expenditure Coverage Ratio | -319.57 | 0.00 |
| Operating Cash Flow Coverage Ratio | -22.84 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 |
| Free Cash Flow Yield | -13.68% | -3.94% |
| Valuation Ratios | ||
| Price-to-Earnings (P/E) Ratio | -2.52 | -46.93 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 5.79 | 1.00 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.31 | -25.38 |
| Price-to-Operating Cash Flow Ratio | -7.33 | -25.38 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.00 |
| Enterprise Value Multiple | -2.62 | -7.08 |
| Enterprise Value | 67.48M | 287.17K |
| EV to EBITDA | -2.62 | -7.08 |
| EV to Sales | 0.00 | 0.00 |
| EV to Free Cash Flow | -6.45 | -3.83 |
| EV to Operating Cash Flow | -6.47 | -3.83 |
| Tangible Book Value Per Share | 2.86 | 18.27 |
| Shareholders’ Equity Per Share | 3.68 | 18.27 |
| Tax and Other Ratios | ||
| Effective Tax Rate | -0.00 | 12.00 |
| Revenue Per Share | 0.00 | 0.00 |
| Net Income Per Share | -8.47 | -0.39 |
| Tax Burden | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 |
| Income Quality | 0.34 | 1.85 |
Currency in CAD
